Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $196

AbbVie, Inc. +0.76%

AbbVie, Inc.

ABBV

178.09

+0.76%

Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE: ABBV) with a Overweight and raises the price target from $193 to $196.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via